retatrutide mechanism triple agonist glp-1 gip glucagon receptor Demonstrated metabolic effects of GIP, and GCG agonism as mono, glp 1 gip triple agonist

The hospital pharmacies segment led the market in 2024, owing to their role in dispensing specialty and high-cost drugs under medical supervision, especially for newly initiated treatments and titration monitoring

Sustainable weight loss requires balanced eating habits, regular exercise, and stress management

GLP-1/dexamethasone inhibits food reward without inducing mood and memory deficits in mice

These effects occurred in 4070% of treated patients in clinical trials

Asia-Pacific is expected to be the fastest growing region in the GLP-1 receptor agonists obesity drugs market during the forecast period due to increasing obesity rates, rising healthcare awareness, and expanding access to advanced diabetes and obesity care Long-acting GLP-1 Receptor Agonists segment dominated the GLP-1 receptor agonists obesity drugs market with a market share of 55.5% in 2024, driven by its superior weight loss efficacy, once-weekly dosing convenience, and broad adoption of drugs such as semaglutide and tirzepatide Report Scope and GLP-1 Receptor Agonists Obesity Drugs Market Segmentation GLP-1 Receptor Agonists Obesity Drugs Market Trends Expansion Beyond Diabetes Through Multi-Indication Approvals A significant and accelerating trend in the global GLP-1 receptor agonists obesity drugs market is the expansion of these therapies beyond type 2 diabetes into broader indications such as chronic obesity, cardiovascular risk reduction, and potentially even conditions such as sleep apnea and nonalcoholic steatohepatitis (NASH)